InvestSMART

Imugene Limited (ASX:IMU)

ALERT: Price-sensitive ASX Announcement for IMU
Current share price for IMU : $0.105 -0.03 (-22.22%)+
Announcement
Release
7 Jul 2026 9:49AM
Price at Release
$0.135
Full Release
download
Summary
Imugene Limited has successfully completed a $11.1 million placement to advance its lead asset, azer-cel, following promising clinical data. This funding will facilitate the expansion of clinical trials, regulatory engagement, and manufacturing efforts for azer-cel, a CAR-T therapy. The placement involved issuing approximately 117.1 million new shares at $0.095 each, managed by Bell Potter Securities. Recent clinical updates included complete responses from patients in the ongoing trials, strengthening the potential for azer-cel in therapeutic markets.
Key Points
  • Imugene Limited completes $11.1 million placement to advance azer-cel.
  • Placement involves issuance of approximately 117.1 million new shares.
  • Shares offered at $0.095 per share, representing a discount to prior prices.
  • Funds to be used for development of azer-cel including regulatory engagement and manufacturing scale-up.
  • Positive clinical responses observed in combination with BTKi in Phase 1b trial.
  • Bell Potter Securities Limited acts as Lead Manager for the Placement.
  • Upcoming data readouts expected over the next 6-12 months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.